A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Glucocorticoids (Primary) ; Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors ReveraGen BioPharma
Most Recent Events
- 16 Oct 2024 Status changed from active, no longer recruiting to completed.
- 30 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Jul 2024.
- 30 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jul 2024.